Alvogen

Montville, United States Founded: 2009 • Age: 17 yrs Acquired By Lotus
Pharmaceutical products are developed and marketed globally.

About Alvogen

Alvogen is a Healthcare company based in Montville (United States) founded in 2009, and was acquired by Lotus in September 2025. Pharmaceutical products are developed and marketed globally. Alvogen has raised $155.92 million across 2 funding rounds from investors including Morgan Stanley, Lotus and IMM Investment. Alvogen has completed 7 acquisitions, including County Line Pharma, County Line Pharmaceuticals and Dolphin. Its chief executive, as recorded, is Lisa Graver. Alvogen offers products and services including Generic Drugs and Injectables. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Alvogen, Inc.

Company details

Alvogen was founded in 2009 and is headquartered in Montville, United States. Operations in the pharmaceutical sector involve developing, in-licensing, manufacturing, and marketing a range of products, including generic drugs, branded items, injectables, and complex medications such as inhalation therapies and 505(b)(2) formulations. A research and development program supports the pipeline, while ethical practices and transparency guide interactions with healthcare providers.

  • Headquarters Montville, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website alvogen.com
  • Social LinkedIn X Facebook
  • Acquired by Aztiq (May 2022)
  • Legal Name Alvogen, Inc
Key Metrics
  • Total Equity Funding
    $155.92M (USD)

    in 2 rounds

  • Latest Funding Round
    $100M (USD), Series D

    Jun 2021

  • Investors
  • Investments & Acquisitions
  • Acquired by
    Lotus

    & 2 more

    (Sep 2025)

Products & Services of Alvogen

Alvogen offers a comprehensive portfolio of products and services, including Generic Drugs and Injectables.

Generic Drugs
Pharmaceuticals

Generic drugs are developed and marketed by Alvogen as part of its core portfolio to provide accessible alternatives to branded medications

Injectables
Pharmaceuticals

Injectables are manufactured and distributed by Alvogen, focusing on complex, high-value products that support various medical treatments

Funding Insights of Alvogen

Alvogen has successfully raised a total of $155.92M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $155.92M
  • Total Rounds 2
  • Last Round Series D β€” $100M
  • First Round $55.92M

    (Jun 2012)

  • Investors Count 2

All 2 funding rounds of Alvogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2021$100MSeries D–Morgan Stanley
–
Jun 2012$55.92MSeries C–IMM Private Equity
–
Valuation history

5 investors in total: 5 institutional.

Investors in Alvogen

Alvogen has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Lotus and IMM Investment.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
IMM Investment is recognized as a leading multi-asset alternative investment firm in Asia.
immpe.comSeoul, South Korea
Private equity investment firm focused on multiple sectors
pamplonafunds.comLondon, United Kingdom
Wealth management, investment advisory, and financial services are provided.
1935morganstanley.comNew York, United States
Aztiq is focused on investments in pharmaceutical and biotechnology sectors.
2009aztiq.comReykjavík, Iceland
Contract manufacturing for oral solid formulations is offered.
1966lotuspharm.comTaipei, Taiwan
Premium access

Investor details for Alvogen

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Alvogen

89 people are tracked at Alvogen (29 in leadership, 5 in board & advisors, 55 in team).

NameRoleGroup
Lisa Graver
CEOLeadership
Robert Wessman
Chairman & CEOLeadership
Arni Hardarson
Deputy to the CEOLeadership
Young-Hoon Kwon
Marketing DirectorLeadership
Lana Puzanova
Senior Director, US ControllerLeadership
joohwa ha
Head Of Commercial Excellence(전무)Leadership
Mohit Patwardhan
Director- Legal and IP Litigation - APACLeadership
Anita Sevcenkova
IP Director B2BLeadership
Renaat Janssen
Executive Vice President APAC | Executive Chairman APACLeadership
William Suchy
Director Of AccountingLeadership
Prashant Godse
Vice President- Business DevelopmentLeadership
Travis Roberts
VP Sales and MarketingLeadership
Dr. Deepali K.
Director, Portfolio & New Products StrategyLeadership
Chia-wei Kin
Director, Chairman office / Special Assistant to APAC CEOLeadership
Eunsun Choi
Vice PresidentLeadership
Gwen Hsieh
VP of IT, Alvogen APACLeadership
John Garbarini
Director of Revenue AccountingLeadership
Evan Lee
Director, Legal AffairsLeadership
Mary Hutchason
Executive Assistant To The Ceo/office ManagerLeadership
Michael Olivi
Senior Director of Sales AlvogenLeadership

69 more people are available in the full profile.

Premium access

Complete people profiles for Alvogen

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Alvogen

Alvogen has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include County Line Pharma, County Line Pharmaceuticals and Dolphin.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Online drug information is provided via GRALISE's digital platform.
gralise.comLake Forest, United States2010Jan 2020$75M
Saline nasal rinse solutions are manufactured for adults and children.
dolphin.ruRussia0Dec 2016β€’β€’β€’β€’
Generic solid and liquid dosage forms are manufactured and marketed.
countylinepharma.comMilwaukee, United States2007Mar 2016$300M
Generic pharmaceutical products are manufactured across therapeutic categories.
countylinepharmaceuticals.comBrookfield, United States2007Mar 2016β€’β€’β€’β€’
Antiviral syrup for children against influenza and infections is manufactured.
orvirem.ruRussia0Jun 2015β€’β€’β€’β€’
Contract manufacturing for oral solid formulations is offered.
lotuspharm.comTaipei, Taiwan1966Jan 2014β€’β€’β€’β€’
Manufacturer of pharmaceuticals and food supplements
labormed.euBucharest, Romania1991Dec 2012β€’β€’β€’β€’
Premium access

Complete acquisition details for Alvogen

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Alvogen

13 dated milestones of Alvogen across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded Alvogen is founded.
  2. Funding First funding round of $55.9M.
  3. Acquisition Acquires Labormed.
  4. Acquisition Acquires Lotus.
  5. Exit Acquired by Pamplona Capital Management.
  6. Acquisition Acquires Orvirem.
  7. Acquisition Acquires County Line Pharmaceuticals.
  8. Acquisition Acquires County Line Pharma.
  9. Acquisition Acquires Dolphin.
  10. Acquisition Acquires GRALISE.
  11. Funding Latest funding round, Series D, of $100.0M.
  12. Exit Acquired by Aztiq.
  13. Exit Acquired by Lotus.

Web traffic of Alvogen

The website of Alvogen (alvogen.com) receives about 9.2K visits a month and ranks #2,534,262 among all websites worldwide, #3,479 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    9.2K

    ▼ 6% vs previous month

  • Unique visitors
    5.1K

    per month

  • Global rank
    #2,534,262

    among all websites

  • Category rank
    #3,479

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Alvogen. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
pharmaceutical-business-review.com
100%
#2,626,966View details
takeda.com
99%
620.1K#93,966View details
parpharm.com
95%
View details
lannett.com
91%
18.2K#1,443,152View details
mylan.com
78%
26.4K#1,585,141View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 17 similar websites and full traffic analytics for Alvogen

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 17 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Alvogen (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Manufacturer of generics formulations
2002Bridgewater, New Jersey, United StatesUSD 3.02 B8,300
Biosimilar therapeutics are developed for oncology and autoimmune diseases.
2010Redwood City, California, United StatesUSD 143.62 MUSD 42.17 M228
Ophthalmic pharmaceuticals and instruments are developed for eye care.
1853Bridgewater, New Jersey, United StatesUSD 5.1 B13,500
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Alvogen

Premium access

Complete news archive for Alvogen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Alvogen

Alvogen was founded in 2009 and raised its 1st funding round 3 years after it was founded.

Alvogen is headquartered in Montville, United States. It is registered at Montville, New Jersey, United States.

Lisa Graver is the CEO of Alvogen, as recorded in our data.

Alvogen is a funded company, having raised a total of $155.92M across 2 funding rounds to date. The company's 1st funding round was a Series C of $55.92M, raised on Jun 2012.

Alvogen was founded in 2009 and is headquartered in Montville, United States. Operations in the pharmaceutical sector involve developing, in-licensing, manufacturing, and marketing a range of products, including generic drugs, branded items, injectables, and complex medications such as inhalation therapies and 505(b)(2) formulations. A research and development program supports the pipeline, while ethical practices and transparency guide interactions with healthcare providers.

Alvogen offers Generic Drugs and Injectables.

Alvogen has made 7 acquisitions, including County Line Pharma, County Line Pharmaceuticals, and Dolphin.

Alvogen has 5 investors. Key investors include Morgan Stanley, Lotus, IMM Investment, Aztiq, and Pamplona Capital Management.

Alvogen operates through Alvogen, Inc.

Yes. Alvogen was acquired by Aztiq in May 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available